Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OD-07656 in Healthy Volunteers
NCT06206811Phase 1Completed
- Sponsor
- Odyssey Therapeutics
- Start
- Feb 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OD-07656 in inflammatory bowel disease (IBD), Blau syndrome and spondyloarthritis (SpA) (4 arms), sponsored by Odyssey Therapeutics. Primary endpoint: Adverse event assessed by Safety review committee at 1 month. Started Feb 2024; status: completed.
02
Drugs
OD-07656
03
Conditions
inflammatory bowel disease (IBD)Blau syndromespondyloarthritis (SpA)
Beyond the preview
Go deeper on NCT06206811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206811.